SinoMab BioScience Ltd. has agreed to terminate a 20-year lease for the SinoMab Building at Haiyao Industry Park in Haikou, effective March 12, 2026. The company said the move supports a shift toward a light-asset manufacturing model, with production for pre-clinical and clinical drug candidates to be outsourced to contract manufacturers. The termination will result in derecognition of a right-of-use asset of about RMB35.8 million and is treated as a connected transaction under Hong Kong listing rules.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SinoMab BioScience Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260312-12049999), on March 12, 2026, and is solely responsible for the information contained therein.